Trial · NCT03425396
Results by group180
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 180
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 300/300 Once Every 24 Hours | Clinical Success | 48 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 450/300 Once Every 24 Hours | Clinical Success | 42 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 450/450 Once Every 24 Hours | Clinical Success | 46 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 450/450 Once Every 12 Hours | Clinical Success | 7 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Nitrofurantoin 100/100 Once Every 12 Hours | Clinical Success | 49 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 300/300 Once Every 24 Hours | Clinical Failure | 5 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 450/300 Once Every 24 Hours | Clinical Failure | 6 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 450/450 Once Every 24 Hours | Clinical Failure | 5 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 450/450 Once Every 12 Hours | Clinical Failure | 0 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Nitrofurantoin 100/100 Once Every 12 Hours | Clinical Failure | 5 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 300/300 Once Every 24 Hours | Indeterminate | 2 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 450/300 Once Every 24 Hours | Indeterminate | 6 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 450/450 Once Every 24 Hours | Indeterminate | 3 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Omadacycline 450/450 Once Every 12 Hours | Indeterminate | 1 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population) | Nitrofurantoin 100/100 Once Every 12 Hours | Indeterminate | 0 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the End of Treatment (EOT) Visit (ITT Population) | Omadacycline 300/300 Once Every 24 Hours | Clinical Success | 49 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the End of Treatment (EOT) Visit (ITT Population) | Omadacycline 450/300 Once Every 24 Hours | Clinical Success | 47 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the End of Treatment (EOT) Visit (ITT Population) | Omadacycline 450/450 Once Every 24 Hours | Clinical Success | 49 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the End of Treatment (EOT) Visit (ITT Population) | Omadacycline 450/450 Once Every 12 Hours | Clinical Success | 7 | Participants | |
| Number of Participants With an Investigator Assessment of Clinical Response at the End of Treatment (EOT) Visit (ITT Population) | Nitrofurantoin 100/100 Once Every 12 Hours | Clinical Success | 49 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03425396/results